PTC Therapeutics Provides Update on German pricing and Reimbursement Process for Translarna™ (ataluren)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to PTC Therapeutics Provides Update on German pricing and Reimbursement Process for Translarna™ (ataluren)
March 1, 2016 7:29 AM EST
Wedbush downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Neutral with a price target of $11.00 (from $27.00), saying lower Translarna estimates shift risk/reward.
Analyst Heather Behanna commented, "Though we still believe Translarna has a good chance of full EU approval, we are... More
March 1, 2016 7:27 AM EST
Cowen downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $7.98 yesterday.
...
More
February 29, 2016 9:32 AM EST
Oppenheimer analyst, Christopher Marai, quantified PTC Therapeutics' (NASDAQ: PTCT) lost opportunity from a failed arbitration process in Germany. More detail will be on today's earnings call after the close but the analyst defines the scope to keep in context. No change yet to the Outperform rating.
PTC announced Friday that an arbitration process with German Federal Association of the Statutory Health Insurances (GKV-SV) concluded with an unacceptable decision. Authorities may have suggested as much as a 65% price reduction, though this is unconfirmed. PTCT is considering removing the drug from the German market;... More
